Releases
19. April, 2021
First quarter report Q1-2021 – ‘one down, two to go’ of the major milestones of 2021
Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1...
Releases
24. March, 2021
Cessatech reports first subject dosed in bioavailability trial of lead product candidate
Clinical trial 0204 in healthy volunteers will investigate the absolute bioavailability of CT001. Primary...
Releases
9. March, 2021
Cessatech A/S is awarded Best Medical Treatment IPO Nordics in 2020 by independent editorial
CFI.co – a journal and online resource reporting on business, economics and finance –...
Releases
4. March, 2021
Favourable data from the Registry Safety Study
First major milestone reached: Data from the Registry Safety Study (0203) indicates a favourable...
Releases
11. February, 2021
Year-end report Q4-2020 – on track and accelerating clinical activities
Cessatech A/S today releases its results for the period 6. April – 31 December 2020. The company is on track with Q4 activities and getting...
Releases
21. January, 2021
Supporting ‘Save the Children’
Cessatech has entered a corporate sponsorship with Save the Children. We want to make...
Releases
27. November, 2020
Cessatech’s IPO of units significantly oversubscribed
Subscribed to DKK 107 million, corresponding to a subscription ratio of approx. 680 percent....
Releases
6. November, 2020
Approval for IPO listing
Cessatech A/S today announces that Spotlight Stock Market’s listing committee has approved Cessatech’s application...
Releases
18. August, 2020
Strong profiles to the Board
The Board has a wide experience from the entire value chain, which is a strong asset for Cessatech and its future aspirations
Want to see all releases?
To see all releases including those not listed here, go to our filings and reports.